Home
Resources
Publications
l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease

l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease

Yoshio Goshima, Daiki Masukawa, Yuka Kasahara, Tatsuo Hashimoto, Aderemi Caleb Aladeokin

Front Pharmacol. 2019 Oct 3;10:1119.

PMID: 31632270

Abstract:

l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson's disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine. In contrast to this generally accepted idea, l-DOPA is proposed to be a neurotransmitter. Recently, GPR143 (OA1), the gene product of ocular albinism 1 was identified as a receptor candidate for l-DOPA. GPR143 is widely expressed in the central and peripheral nervous system. GPR143 immunoreactivity was colocalized with phosphorylated α-synuclein in Lewy bodies in PD brains. GPR143 may contribute to the therapeutic effectiveness of l-DOPA and might be related to pathogenesis of PD.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP53587294	L-Dopa-(phenyl-d3)		53587-29-4	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: